Blackrock Neurotech — Invasive Cortical Implants · fobi

Blackrock Neurotech

Manufactures the Utah Array and other electrode systems used in academic BCI research and clinical trials for over a decade. Originally Blackrock Microsystems; rebranded in 2021. Supplies research-grade arrays to institutions and is moving toward commercial medical products.

The longest-running commercial implant platform in the field, with devices in dozens of human subjects and a track record spanning clinical milestones like typed speech and robotic-arm control.

blackrockneurotech.com Invasive Cortical Implants

United Statesprivate

At a glance

Total raised

Undisclosed

no public funding on record

Headcount

51-200

approximate · public range

Headquarters

Salt Lake City

United States

Founded

2008

18 years active

Status

Private

Invasive Cortical Implants

Latest valuation

For subscribers

Subscribe to see the full profile

Including Funding rounds, Bull / Bear thesis, Stock + earnings, Roster changes, Patents, News, and Open roles.

Already subscribed? Sign in →

Date	Stage	Amount	Valuation	Lead investors
Apr 29, 2024	Acquired	$200M	$350M	Tether
May 19, 2021	Series A	—	—

AI bull / bear

Bull case

Blackrock Neurotech owns the only implant platform with a sustained human track record in BCI. The Utah Array has been implanted in dozens of subjects over more than a decade, producing the safety data and clinical evidence that no competitor can match. That installed base is a moat: every new implant carries risk, but Blackrock's device has the longest safety record in the field. The company has already been part of landmark demonstrations — typed speech, robotic-arm control — giving it credibility with regulators and clinicians that well-funded newcomers lack. As the field shifts from academic experiments to commercial therapies, Blackrock can leverage this head start to secure FDA approvals and physician preference before newer entrants clear their own hurdles. The rebrand from Blackrock Microsystems in 2021 signaled a strategic pivot from research-tool supplier to medical-device company, a move that positions it to capture value from the clinical milestones it enabled for others.

Bear case

Blackrock has not disclosed any funding rounds, which in a capital-intensive field like invasive BCI is a red flag. The Utah Array is an older design — a rigid, penetrating electrode platform — at a time when competitors are developing softer, wireless, higher-channel-count or less invasive alternatives. Synchron's stent-electrode requires no craniotomy; Neuralink is aiming for dramatically higher channel density. Blackrock's technology, while proven, may be commercially obsolete before it reaches its first approved product. The company is also caught between two worlds: it has been a supplier to academic labs for years, but transitioning from research-grade hardware to a regulated medical device requires a fundamentally different manufacturing, quality, and clinical-trial infrastructure. Without a disclosed capital base, it is unclear whether Blackrock has the resources to fund these programs against well-financed rivals, and the absence of recent public milestones suggests the company may be stalling rather than accelerating.

Generated by deepseek-v4-flash · June 2, 2026Refreshes quarterly · see disclosures

Blackrock Neurotech

At a glance

Subscribe to see the full profile

Funding history

How they make money

Founder backgrounds

Florian Solzbacher

Marcus Gerhardt

AI bull / bear

In the news

Watch

Leadership

Products

Utah Array

MoveAgain BCI System

Open roles

Compare Blackrock Neurotech with